CRISPR-edited stem cells shield blood cells from cancer therapy in trial

Researchers have utilized CRISPR technology to remove the CD33 protein from donor stem cells, a modification that could enable physicians to treat aggressive blood cancers while preserving the healthy cells required following a transplant. This approach aims to protect essential blood cells from the collateral damage typically associated with CD33-targeted cancer therapies.

In a clinical trial involving 30 patients, the genetically edited cells successfully engrafted and demonstrated the ability to shield blood cells from the CD33-targeted treatment. This outcome suggests that the modified donor cells can persist in the body while providing the intended protection against the therapeutic agent.